PI
ALT icon

Pennant Investors’s Altimmune ALT Stock Holding History

Pennant Investors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-109,800
Closed -$730K – 20
2024
Q2 		$730K Hold
109,800
– – 0.19% 19
2024
Q1 		$1.12M Hold
109,800
– – 0.28% 15
2023
Q4 		$1.24M Buy
+109,800
New +$458K 0.27% 12

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pennant Investors's ALT Position: Q3 2024 in Review

Pennant Investors sold out of Altimmune (ALT) in Q3 2024, closing a stake of 109,800 shares — an estimated $730K sold.

Pennant Investors first reported a position in ALT in Q4 2023 and held it in 3 quarters. The position peaked at $1.24M in Q4 2023. 169 funds tracked by Wall St. Rank hold ALT as of Q3 2024.

  • Pennant Investors reported no remaining Altimmune position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 109,800 Altimmune shares in Q3 2024, an estimated $730K.
  • Pennant Investors first reported a position in Altimmune in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Altimmune position peaked at $1.24M in Q4 2023.
  • 169 funds tracked by Wall St. Rank held Altimmune as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.